Understanding H Syndrome and its Treatment Responses

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on H syndrome, a rare genetic disorder that predisposes patients to histiocytosis due to mutations in the SLC29A3 gene. The study aims to comprehensively assess the clinical manifestations and treatment responses of a multinational cohort of patients diagnosed with H syndrome. By analyzing data from these patients, the researchers hope to identify patterns in treatment efficacy and improve understanding of the disease's clinical spectrum. The study builds on previous findings that suggest a novel signaling pathway involved in the disease's pathology.

Why it matters

Who can join: the full rules

Inclusion Criteria: Any patient with a genetically confirmed diagnosis of H syndrome -

Exclusion Criteria:

\-

Where it's running

• Schneider Children's Medical Center
  Petah Tikva, Israel Recruiting

Study contacts

• Study coordinator: Sarah Elitzur, MD
• Email: sarhae@clalit.org.il
• Phone: +97239253766

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 1-Year Recurrence After En Bloc Resection for Large Bladder Tumors

  This trial tests whether en bloc resection of bladder tumors larger than 2.5 cm can reduce recurrence compared with standard transurethral resection in adults with non-muscle invasive bladder cancer.

  Recruiting Phase 3 Rabin Medical Center · Petah Tikva · NCT07898033

• Once-weekly somatrogon versus daily growth hormone for children with short stature (SGA or ISS)

  The study will test whether a once-weekly somatrogon injection works as well and is as safe as daily Genotropin for prepubertal children with short stature due to being born small for gestational age (SGA) or idiopathic short stature (ISS).

  Recruiting Phase 3 Rabin Medical Center · Los Angeles, California and 31 other locations · NCT07226089

• Tb-PSMA radionuclide treatment before radical prostatectomy for locally advanced prostate cancer

  This will try giving a Tb-PSMA radionuclide treatment to men with high-risk, locally advanced prostate cancer before prostate removal to see if it is safe and reduces tumor burden.

  Recruiting Phase 1/2 Rabin Medical Center · Petah Tikva · NCT07208240

• Evaluation of a dosing guidance system for diabetes management

  This study is testing a new system that helps people with Type 1 and Type 2 diabetes manage their insulin doses better to see if it improves their blood sugar control.

  Recruiting Rabin Medical Center · Petah Tikva and 1 other locations · NCT06966427

• Adding the immunotherapy drug tislelizumab to total neoadjuvant treatment for locally advanced rectal cancer

  This trial will test whether giving the immunotherapy drug tislelizumab together with total neoadjuvant treatment helps people with locally advanced rectal cancer avoid major surgery.

  Recruiting Phase 2 Rabin Medical Center · Mainz and 1 other locations · NCT06940388

• Combining Palbociclib and Sunitinib for treating advanced solid tumors

  This study is testing if a combination of two cancer drugs, Palbociclib and Sunitinib, can help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting Phase 1/2 Rabin Medical Center · Petah Tikva · NCT06940349

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.